Onset: 15-30 min sublingual; 30-60 min oral.

Duration: Acute subjective effects 3-6 hours; some users report a "halo" effect persisting into the next day at consistent dosing (matches the 24-hr functional duration in animal models).

Characteristic effects (synthesized from Longecity, PsychonautWiki, Reddit, and the n=1 case study):

• Visual changes are the headline effect. Most reproducibly reported: increased color saturation, especially in already-bright objects (sky, foliage, screens); expanded dynamic range (darker darks, brighter brights); sharper perceived edges; "HDR-like" or "everything in HD" descriptors recur across hundreds of reports. The effect is not psychedelic — there are no patterns, no morphing, no closed-eye visuals — it's described as the world looking more like itself, sharper. Onset typically within 30-45 minutes of sublingual dosing.
• Mild cognitive lift — improved focus and "thought flow," often described as smoother than pramiracetam (less stimulating, less "sharp").
• Anxiolytic component (variable) — about 1/3 of users report a calming background effect at 5-10 mg; some report this most strongly in social situations.
• Auditory and tactile sensitization (less reproducible) — some users report sound and touch feeling more textured. Less consistent than the visual signature.
• Dream potentiation — vivid dreams the night after dosing are reported by a subset. Cholinergic-REM mechanism plausible.

Variability: High. The visual effect is the most reproducible — but ~20-30% of users report no detectable subjective effect at any dose. Some users describe nothing at 5-10 mg but report the visual signature only at 20 mg+. A subset report that the effect builds with several days of consistent dosing rather than appearing on first dose, suggesting CHT1 trafficking takes time to accumulate.

What it does NOT feel like:

• Not a stimulant (no caffeine/modafinil-like wakefulness drive)
• Not a euphoriant (no mood lift comparable to bromantane or amphetamines)
• Not a dissociative or psychedelic (visual changes are perceptual sharpening, not distortion)
• Not a strong anxiolytic by itself (the calming effect is mild and unreliable)

• Tolerance buildup: Reported as moderate by users. PsychonautWiki: "tolerance develops with prolonged and repeated use," recovery to 50% baseline in 3-7 days, full reset 1-2 weeks. Cross-tolerance with other racetams suspected (mechanism shared at the cholinergic-system level even if receptor targets differ).

• Recommended cycle: PRN use only — 2-4×/week maximum during active use. If running daily for a project block, cycle 4 weeks on, 1-2 weeks off.

• Reset protocol if needed: 1-2 weeks off restores full subjective effect for most users. Some report needing 3-4 weeks if heavy daily use was prolonged.

Synergistic with

• citicoline (already in Dylan's V4 at 500 mg/day) — Citicoline raises systemic choline + provides cytidine for phospholipid synthesis. Coluracetam needs adequate intracellular choline to express its CHT1-trafficking effect. This is the canonical pairing. No additional choline donor needed if citicoline is already in stack.
• alpha-gpc — Alternative choline donor; raises brain choline more aggressively than citicoline. Use this only if citicoline is not in the stack — don't double-stack alpha-GPC + citicoline + coluracetam (no evidence it helps, and over-cholinergic tone can cause headache/depression). Standard alpha-GPC dose if pairing: 300-600 mg.
• aniracetam — Mood-and-memory racetam with a different mechanism (AMPA receptor modulation + 5-HT2A modulation). Some users stack aniracetam 750 mg + coluracetam 10 mg for a "creative-visual" combo. Plausible mechanism overlap (both depend on cholinergic baseline) without direct competition. Anecdotal only.
• dha / fish oil (already in Dylan's V4 at 2 g/day) — Substrate-level support for cholinergic neurons; phosphatidylcholine synthesis depends on DHA availability. Not a direct synergy but a foundational stack element.

Avoid stacking with

• pramiracetam — Both work via HACU enhancement (different binding profile but same downstream pathway). Stacking is mechanistically redundant and may push cholinergic tone too high. If using one, don't also use the other. For Dylan, given pramiracetam is the encyclopedia recommendation for daily memory/focus, coluracetam is best treated as an alternative or PRN replacement, not a co-administered tool.
• other HACU enhancers in development — None on the gray market currently, but if any emerge (e.g., fresh CHT1 modulators in research), avoid stacking on the same principle.
• strong AChE inhibitors (donepezil, high-dose huperzine A) — Coluracetam raises ACh synthesis ceiling; AChE inhibitors slow ACh breakdown. Combining could produce cholinergic excess (sweating, GI cramping, fatigue). Low-dose huperzine A (50-100 mcg) probably fine; donepezil-class drugs avoid.
• anticholinergics (diphenhydramine, dicyclomine, scopolamine) — Direct mechanistic opposition. No safety risk but defeats the purpose. Note that many sleep aids (Benadryl, doxylamine) are anticholinergic — separate by 6+ hours.

Neutral / safe co-administration

Modafinil, bromantane, semax, selank, NAC, magnesium (Magtein + glycinate per V4), phosphatidylserine, curcumin, rhodiola, theanine, glycine/tryptophan, D3+K2, beta-alanine, vitamin C, creatine, taurine, ALCAR. The full V4 stack is compatible — coluracetam slots in as a PRN add without conflicts.

• CYP enzymes: No published data on CYP induction or inhibition by coluracetam. The Phase 2a trial did not report drug-interaction findings. Treat as unknown — caution if combining with narrow-therapeutic-index drugs.
• Hormonal contraceptives: No known interaction (relevant for partners, not Dylan directly).
• MAOIs (selegiline included): No published interaction. Selegiline at MAO-B-selective doses (1-2.5 mg) should be safe to co-administer mechanistically, but no controlled data exists. Flag if Dylan ever increases selegiline dose into MAO-A territory (≥10 mg).
• SSRIs/SNRIs: No published interaction. The BrainCells Phase 2a trial enrolled patients who had failed prior antidepressants; many would have been washed out, but the trial design did not specifically prohibit concurrent stable-dose SSRIs. Consider as low-likelihood-interaction.
• Stimulants (caffeine, modafinil, amphetamines): Anecdotally co-used without issues. Some users report the visual signature is sharpened by caffeine co-administration. No safety concerns identified.
• Alcohol: Standard depressant interaction — no specific coluracetam pharmacology, but PsychonautWiki flags general risk of respiratory depression/aspiration if mixing with high-dose depressants. Not relevant for Dylan (zero alcohol baseline).

• SLC5A7 polymorphisms: The CHT1 gene (SLC5A7) has known polymorphisms affecting choline uptake function (e.g., I89V variant associated with altered transporter activity). Whether these polymorphisms predict coluracetam response is untested. If 23andMe data covers SLC5A7 variants, this could be retrospectively informative but not actionable up-front. Low priority for Dylan's June 2026 genetics interpretation phase.
• CHAT, BCHE polymorphisms: Choline acetyltransferase and butyrylcholinesterase variants modulate cholinergic baseline. Could plausibly influence coluracetam response magnitude but no studies have looked.
• CYP polymorphisms: Without published metabolism data on coluracetam, CYP2D6/CYP3A4 status cannot be linked to exposure. Unknown clinical relevance.

Estimated cost for Dylan's PRN use case: At 5-10 mg dosing 2-3×/week, a single 1 g jar (~$15-19 from Nootropics Depot) lasts 3-6 months. Annualized ~$30-50/year, not /month — this is one of the cheapest racetams to run PRN.

Sublingual liquid form: Some vendors offer pre-mixed coluracetam in a propylene glycol or DMSO solution with dropper. Convenient for sub-mg precision dosing but check the vehicle (some users react to high-dose PG). DIY: dissolve weighed powder in food-grade propylene glycol or olive oil for sublingual administration.

Form considerations: Coluracetam powder is reportedly bitter and not water-soluble — dry sublingual powder is unpleasant; capsules or liquid solutions are preferred. Note one Longecity thread (Nootropics Depot 2018-era batch) where users reported lower-than-expected potency, attributed to a quality issue at the time; current Nootropics Depot QC is reportedly tighter.

Regulatory status: Unscheduled in the US, EU, UK, Canada, Australia. Not approved for human consumption; sold as research chemical. No FDA enforcement actions specific to coluracetam are documented as of 2026. WADA: not on the prohibited list (irrelevant for Dylan's untested status either way).

• Baseline (before starting): Subjective baseline — write down what colors look like in 3-5 environments (sky, screens, faces, food, foliage). Photograph a known-color reference (a Pantone card or saturated-color object) under fixed lighting. Rate visual subjective quality 1-10. This is the only way to retrospectively assess the visual-perception claim — it's so subjective that without a baseline you'll be susceptible to placebo or post-hoc rationalization.
• During use: Re-check the same baseline references at 30 min, 60 min, 2 hr, 4 hr post-dose. Note dream vividness (1-10 scale) the night after dosing. Subjective focus rating during work block.
• Post-cycle (if cycled): Re-check baseline visual rating off-drug to see if effect was attribution or actual. Note any persistence of effect 24-48 hr post-dose.
• No bloodwork specifically indicated. No reliable biomarker exists for HACU activity in vivo. The Phase 2a trial used HAM-D / HAM-A scales for outcome — not relevant for nootropic use.